Literature DB >> 15965665

[Palliative pain therapy, cannabinoids].

L Radbruch1, F Elsner.   

Abstract

Cancer pain treatment should follow the recommendations of the World Health Organisation. Treatment should be with oral application, regular application times and following the analgesic step-ladder. Non-opioids such as dipyrone or non-steroids are used for slight to moderate pain, step-2 opioids such as tramadol or tilidine/naloxone for moderate pain and step-3 opioids such as morphine, oxycodone or hydromorphone for severe pain. Transdermal application of fentanyl or buprenorphine offer a non-invasive parenteral alternative for patients with stable pain syndromes. Cannabinoids such as tetrahydrocannabinol offer a valuable add-on option for cancer patients with refractory pain, spasticity, nausea or appetite loss.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15965665     DOI: 10.1007/s00108-005-1442-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  26 in total

Review 1.  Cannabinoids on trial for multiple sclerosis.

Authors:  John Zajicek
Journal:  Lancet Neurol       Date:  2002-07       Impact factor: 44.182

Review 2.  Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana.

Authors:  J M McPartland; P L Pruitt
Journal:  Altern Ther Health Med       Date:  1999-07       Impact factor: 1.305

3.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.

Authors:  Jonathan S Berman; Catherine Symonds; Rolfe Birch
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

4.  Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Authors:  Derick T Wade; Petra Makela; Philip Robson; Heather House; Cynthia Bateman
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

5.  Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  C Vaney; M Heinzel-Gutenbrunner; P Jobin; F Tschopp; B Gattlen; U Hagen; M Schnelle; M Reif
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

6.  Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.

Authors:  Barbara Donner; Michael Zenz; Michael Tryba; Michael Strumpf
Journal:  Pain       Date:  1996-03       Impact factor: 6.961

7.  Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?

Authors:  C Ripamonti; L Groff; C Brunelli; D Polastri; A Stavrakis; F De Conno
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

8.  An analgesia circuit activated by cannabinoids.

Authors:  I D Meng; B H Manning; W J Martin; H L Fields
Journal:  Nature       Date:  1998-09-24       Impact factor: 49.962

9.  Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain.

Authors:  Donal J Buggy; Lynn Toogood; Shelagh Maric; Paul Sharpe; David G Lambert; David J Rowbotham
Journal:  Pain       Date:  2003-11       Impact factor: 6.961

10.  [MIDOS--validation of a minimal documentation system for palliative medicine].

Authors:  L Radbruch; R Sabatowski; G Loick; I Jonen-Thielemann; F Elsner; E Hörmann
Journal:  Schmerz       Date:  2000-08       Impact factor: 1.107

View more
  1 in total

1.  [Chronic pain therapy for patients with head and neck tumors].

Authors:  A Walz; B Haberland; B Wollenberg; C Bausewein
Journal:  HNO       Date:  2006-10       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.